POST-REGISTRATION STUDY OF THE EFFICACY AND SAFETY OF ANGIOTENSIN CONVERTING ENZYME’S INHIBITOR RAMILONG (RAMIPRIL) IN CLINICAL PRACTICE
In post-registration study the efficacy and safety of angiotensin converting enzyme’s inhibitor Ramilong (ramipril) in routine clinical practice were examined. In an open, prospective, 7-21 day study 64 patients with mild to moderate hypertension were included. Treatment by Ramilong was started with a dose of 2,5-5,0 mg once a day. The dose to achieve the reduction of blood pressure (BP) to the target values was gradually increased. Efficacy was assessed in all 64 patients whose blood pressure was recorded after the initiation of treatment. Safety was also determined in all patients (n = 64). Ramilong reduced systolic and diastolic blood pressure by 20% and 17% respectively. The decrease in diastolic blood pressure below 90 mm Hg was achieved in all patients with systolic-diastolic hypertension. A more pronounced decrease in diastolic blood pressure was observed in the elderly. The decrease in systolic blood pressure below 140 mm Hg was observed in all patients with isolated systolic hypertension. Greater reduction in systolic blood pressure was observed in the elderly. All patients underwent therapy by Ramilong during hospital treatment. Adverse reactions were reported in 7,8% of patients, were readily expressed and did not require discontinuation of therapy. Cough is most common (4,7%). Thus, the 7-21 day study demonstrated the efficacy and tolerability of Ramilong in patients with mild to moderate hypertension, which were hospitalized.